ArticleFunctional & integrative genomics2026
IFI6 is associated with interferon activation and complement-associated immune responses in primary Sjögren's disease.
Article in Functional & integrative genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary Sjögren's disease (pSjD) is a systemic autoimmune disease characterized by chronic immune-mediated inflammation of exocrine glands and a prominent type I interferon (IFN-I) signature. However, the molecular mechanisms linking interferon signaling with downstream immune and inflammatory pathways in pSjD remain incompletely understood. In this study, we performed an integrative analysis combining public transcriptomic datasets, immune infiltration analysis, single-cell RNA sequencing, and experimental validation to investigate the potential involvement of interferon alpha-inducible protein 6 (IFI6) in pSjD. Differential expression and network analyses identified IFI6 as an upregulated interferon-stimulated gene associated with immune-related pathways. Immune infiltration analysis showed that IFI6 expression was associated with activated dendritic cells and CD4⁺ memory T cells. Single-cell RNA sequencing further indicated preferential expression of IFI6 in dendritic cell subsets. Clinical validation revealed increased serum IFI6 levels in patients with pSjD, which were negatively associated with salivary flow rate. In addition, immunoprecipitation coupled with proteomic analysis identified complement-related proteins within IFI6-associated complexes, and enrichment analysis suggested the involvement of complement activation pathways. Overall, these findings indicate that IFI6 expression is associated with interferon-related immune activation and complement-associated inflammatory pathways in pSjD. IFI6 may serve as a potential biomarker reflecting interferon-related immune activation and is associated with reduced salivary flow rate in pSjD, although further studies are required to clarify its precise functional role.
Indexed as
Identifiers
42552444What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.